Amgen stock falls after HSBC cuts its rating
Published on 09/12/2026 at 14:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Amgen stock (ISIN US0311621009) closed at USD 377.35 on September 11, 2026, down USD 5.12 or 1.34 percent, with a market cap of USD 204.01 billion and a 52-week range of USD 269.77 to USD 447.03. The latest catalyst is HSBC's downgrade, which cut the shares to Hold from Buy and reduced the price target to USD 425 from USD 445, according to ad hoc news on September 10, 2026.
Q2 revenue beat consensus
Amgen reported Q2 2026 revenue of USD 10.05 billion and earnings per share of USD 6.29, ahead of consensus for USD 9.43 billion and USD 5.62, according to MarketBeat. The company said revenue rose 9.5 percent year over year, while EPS improved from USD 6.02 in the prior-year quarter.
Repatha drives the debate
One market focus is Repatha, which posted USD 953 million in Q2 2026 revenue, up 37 percent year over year, and 35 percent volume growth, according to MarketBeat. The same report said Amgen's stock fell nearly 10 percent on September 8, 2026 and was down more than 12 percent over the five trading days ending September 10.
Stock near its range
At 4:00 PM Eastern on September 11, 2026, Amgen traded at USD 377.35, with intraday volume of 759,306 shares and a consensus price target of USD 381.68 on MarketBeat. The stock sits 15.6 percent below its 52-week high of USD 447.03 and 39.9 percent above its 52-week low of USD 269.77.
Amgen stock at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of September 11, 2026, 4:00 PM): USD 377.35
- Market capitalization: USD 204.01 billion (as of September 11, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Index membership: S&P 500
